Cantor Fitzgerald assumed coverage on shares of CG Oncology (NASDAQ:CGON – Free Report) in a research report released on Tuesday morning, MarketBeat Ratings reports. The brokerage issued an overweight rating and a $75.00 target price on the stock. Cantor Fitzgerald also issued estimates for CG Oncology’s FY2023 earnings at ($1.23) EPS, FY2024 earnings at ($1.36) […]